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Aspects of dyslipidaemia in
diabetes mellitus
F J Mantz
Dyslipidaemia in diabetes was referred to by Joslin as early
as 19271 and has been the subject of numerous articles.2....
Very often little attention is paid to dyslipidaemia, which
plays a major role in the premature development of
atherosclerosis in diabetes. It is now increasingly recognised
that diabetes is not only a disorder of carbohydrate
metabolism but also of lipid and protein metabolism, and
attention should be given to these other metabolic aspects
and not only the glycaemic control of the diabetic patient.
This article is not intended to be exhaustive, but aims rather
to focus attention on the importance of dyslipidaemia in the
management of diabetic patients. An overview is given of
some of the pathophysiological processes that lead to
dyslipidaemia in diabetes, the changes in lipids and
lipoproteins that are seen are briefly described, and an
outline of the management is presented.
Atherosclerosis and diabetes
Atherosclerosis affects the majority of diabetics and
coronary vascular disease (CVO) is the leading cause of
death.~ All the manifestations of atherosclerosis occur more
commonly and with increased severity, and these have been
clearly documented in prospective studies such as the
Framingham study.e Coronary artery disease (CAD) and
cerebrovascular disease are two to three times more
frequent, and peripheral vascular disease is four times more
frequent, in diabetics than non-diabetics. '1 The gender
difference in the prevalence of atherosclerosis disappears in
diabetes and the incidence in women approaches that in
men.s Not only is atherosclerosis more prevalent, but it also
appears to be more extensive in diabetics.·o It therefore
stands to reason that dyslipidaemia as a risk factor for
atherosclerosis should receive more attention than it
currently does.
Pathophysiological processes
that lead to dyslipidaemia in
diabetes
Numerous changes that may lead to dyslipidaemia3 occur in
diabetes (fable I), and these may be present in combination,
or may arise when the patient is already diabetic or poorly
controlled; others, however, may arise before the patient is
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overtly diabetic when he/she only has impaired glucose
tolerance:' A lack of insulin action characterises diabetes
but the mechanism by which this lack of insulin action arises
in the two major types of diabetes differs, viz., a lack of
insulin production in insulin-dependent diabetes mellitus
(lOOM) and a resistance to the action of insulin, primarily at
post-receptor level, in non-insulin-dependent diabetes
mellitus (NIDOM);l~ it is this difference that underlies the
differences in the lipoprotein and lipid profiles seen in these
two forms of diabetes.
Lipoprotein lipase (LPL). LPL is the key enzyme involved
in the catabolism of triglyceride (TG)-rich lipoprotein
particles of intestinal and hepatic origin, namely
chylomicrons and very-lOW-density lipoprotein (VLDL)
respectively, Il which leads to the formation of relatively TG-
rich remnants, also referred to as chylomicron remnants and
intermediate-density lipoproteins (IDLs) respectively. These
are subsequently cleared from the circulation by their
respective ApoE binding receptors or, in the case of IOL,
further metabolised to low-density lipoprotein (LOL). LPL is
an endothelially located inSUlin-dependent enzyme;·~ with
reduced insulin action there is consequently a reduced
catabolism of the TG-rich particles such as chylomicrons
and VLDL, which leads to an accumulation of their remnants
which in turn results in an increase in serum TG. When the
deficiency in insulin action is severe this Can lead to
'diabetic lipaemia' or a chylomicronaemia syndrome. There
is an established inverse relationship between TG and
HDL, 1~ and HDL is consequently reduced. The activity of the
insulin-dependent hepatic trigtyceride lipase, which is
involved with the further metabolism of the remnants, is also
reduced and contributes to the impaired remnant clearance.
The reduced activity of these lipases also leads to a relative
TG enrichment of LDL. ,e The accumulation of TG-rich
particles and the TG enrichment of LDL have both been
shown to be associated with increased atherogenicity.
Increased VLOL secretion by the liver. In diabetes an
increased secretion of VLDL by the liver has been
demonstrated; this contributes to the increase in serum TG.
On the one hand, this may be a result of the increased flux
of non-esterified fatty acids from the periphery to the liver
due to a loss of the peripheral antilipolytic action of insulin.n
On the other hand the increased VLDL secretion has been
associated with the hyperinsulinism seen with insulin
resistance, and these increased insulin levels have in the
past, quite wrongly, been directly implicated in the increased
VLOL secretion. However, insulin has clearly been shown to
have an inhibitory effect on VLDL secretion. 11 Furthermore,
microsomal transfer protein, the protein involved in the
addition of lipids to ApeB and the assembly of VLDL prior to
secretion by the liver, is negatively controlled by insulin.·'
The increased VLDL secretion is therefore a further
manifestation of the intra-hepatic lack of insulin action; the
hyperinsulinism should be seen as a compensatory
response to insulin resistance and loss of insulin action, and
does not lead directly to the increased VLDL secretion.~
Impaired reverse cholesterol ester transport. There is
an impaired trar.sfer of esterified cholesterol from HDL to
VLDL (reverse cholesterol transport) despite the normal
activity of lecithin cholesterol acyltransferase; this leads to
an altered lipid content of these particles, which is most
probably the resutt of an increased cholesterol content in the
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Table I. Pathophysiological processes which may occur in diabetes and lead to development of dyslipidaemia
Change in diabetes
J, Upoprotein lipase (HTL)
J.- Hepatic triglyceride lipase (HTL)
J, LDL receptor activity
J, Lecithin cholesterol acyl transferase (LeAl)




VLoL and LDL of diabetics.2!I Similar changes have been
found in other conditions where there is a high risk for CAD.
LDL clearance. LDl particles are formed by the
progressive metabolism and TG removal from VLDL and lol,
which leads to a cholesterol-rich particle that is then cleared
from the circulation by the LDL receptor or pathologically
deposited in peripheral tissues. Binding of LDL to the LDl
receptor and subsequent internalisation are partially
regulated by insulin, and a decreased clearance of LDL at
the level of the LDL receptor has been demonstrated in
diabetes.21 However, a markedly increased serum LDL
cholesterol (LoL-C) level is not a common feature in
diabetics because the effect of the reduced clearance of
LoL particles is, to a degree, offset by the reduced
production of LoL particles as a result of the impaired
metabolism of VLOL and IDL
Glycosylation. As with other proteins, apoproteins are
prone to glycosylation in diabetics, with a resultant
impairment of their normal functions.22.23 Glycosylation of
ApoB, the receptor-binding moiety of LoL, interferes with
LDL clearance.2' LoL also reacts with tissue-derived
advanced glycation end-products and this process is
worsened with renal impairment, where there is reduced
clearance of these products. Glycosylation of LoL further
enhances and accelerates the uptake of LDL by
macrophages via the 'scavenger' receptors, and part of this
accelerated uptake may be due to the enhanced ability of
glycosylated LoL to be oxidised. Glycosylation of collagen
leads to products that have an enhanced ability to trap LDL
and aggravate lipid accumulation in peripheral tissues.25
ApoE glycosylation interferes with its binding to E-binding
receptors and further impairs the clearance of VLDL and
remnants. 22
Oxidation. Of late, much attention has been given to the
oxidation of lipoproteins in the genesis of atherosclerosis.
LDL is only taken up by the 'scavenger receptors' of
macrophages after modification, usually by oxidation.
Furthermore, these scavenger receptors are not
downregulated, which leads to the progressive lipid
accumulation in macrophages and formation of foam cells.
Oxidation of LDL therefore stimulates the progression of
atherosclerosis and also stimulates the release of
chemotactic factors that attract macrophages to areas of
lipid accumulation.26 The small dense LDL particles that
accumulate in insulin resistance are even more prone to
oxidation, which thus increases the tendency to
atherosclerosis, despite relatively normal levels of LDL-C.
ApoS is also more prone to oxidation in diabetic than in
non-diabetic patients.27
Effect on lipids
i TG, J, HDL, remnants, chylomicronaemia
i remnants, chylomicronaernia
i LDL
Altered content of lipoproteins
Altered content of Iipoproteins
i TG
Altered apoprotein function
Increased peripheral uptake of LDL
Other genetic factors. Diabetic patients, although they
inherit certain genes that predispose them to diabetes, are
not impervious to the other genetic influences that
determine abnormal lipid profiles in the general population.
The distribution of different ApoE phenotypes, which
significantly influence variability of cholesterol
concentrations in the general population, is no different in
diabetics than the general population.26 Other non-diabetic
factors, either genetic or environmental, affect the
background lipid profile of a diabetic patient and this
background is further modified by the diabetic state.
Furthermore, the gene or genes that cause insulin resistance
in type 11 diabetes are also likely to affect the lipid profile
directly. The lipid profile in type II diabetes is therefore not
solely the result of hyperglycaemia, poor control or the
diabetic state.
The lipid profile in diabetes
mellitus
The lipid profile in diabetes29 is complex and modified by
various factors such as the presence of insulin resistance,
degree of glycaemic control and the interaction of the
genotype with various environmental influences.
The lipid profile in IDDM. The lipid profile in lOOM (type I)
is, for the most part, dependent on the degree of control of
the diabetes and the dosage of insulin. In contrast to
NIDDM, the processes that lead to the diabetes are
independent of lipoprotein metabolism and do not influence
the lipid profile. In the uncontrolled state high TG and lower
HDL levels are found, but these may vary from an extreme
situation such as a chylomicronaemia syndrome to values
that appear entirely normal. This predisposition to develop
the chylomicronaemia syndrome may itself be associated
with other genetic factors, of which an ApoE2 homozygosity
is but one example.2.3ll Almost all studies have shown
relatively normal or even increased HoL levels when
treatment is optimal and stabilisecf.J1 Mild increases in total
cholesterol (TC) and LDL-C levels are occasionally seen32 but
for the most part the lipid profile in optimally controlled
lOOM tends to be normal and any residual abnormalities
may well be a reflection of the background lipidogenic
genetic and environmental influences of that particular
population. The improvements in the lipid profile after
glycaemic control are the highest for TG and TC, with lesser
changes in HDL3J The gender differences in cardiovascular
disease mortality usually seen in non-diabetics are reduced
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in lOOM and abnormalities in the lipid profile are more
pronounced in women with lOOM than in men.~ The lipid
profile is further worsened by the presence of renal
disease.:l5 which is one of the major determinants of
dyslipidaemia in NIOOM. Furthermore, micro-albuminuria is
predictive of the later development of dyslipidaemia and
cardiovascular complications.~
Apart from the quantitative changes described above,
certain qualitative and compositional changes occur that
may account for some of the atherogenicity of the
lipoproteins, despite relatively normal circulating levels of
TC. High free cholesterol/lecithin ratios are seen in VLOL
and LoL, which may interfere with lipid transfer and reverse
cholesterol transfer, including the ability of HDl to accept
cholesterol from peripheral cells. Furthermore. these
changes do not fully return to normal after optimisation of
treatment. Small dense LoL is also increased in lOOM but
not to the same degree as in NIOOM.
The lipid profile in NIDOM,31 Lipid abnormalities are more
common in NIOOM (type 11) than in lOOM and the underlying
genetic factors that predispose to the development of insulin
resistance and NIOOM also directly influence lipoprotein
metabolism and the lipid profile. Much attention has been
given to the coexistence of a complex of abnormalities that
largely determines the lipid profile in type 11 diabetic patients.
viz. insulin resistance, hyperinSUlinism, central obesity.
hypertension, dyslipidaemia with high TG and low Hol.
hyperuricaemia, increased plasminogen activator inhibitor
levels. hyperfibrinogenaemia and a marked propensity to
develop atherosclerosis and coronary heart disease, also
referred to as the insulin resistance syndrome, syndrome X
or the plurimetabolic syndrome.3I.JlI The lipid profile and
factors that lead to atherogenesis in the insulin resistance
syndrome are complex, occur early and are present before
the appearance of overt dIabetes and are predictive of the
development of NIOOM." High triglyceride values are seen·~
and are, to a large degree, the result of impaired lPL
activity" with consequent higher levels of lol Together WIth
the high TG, low HOl values are found, and the usual
gender difference seen in the HDL levels of non-diabetics
disappears in NIDoM. To a degree, the dyslipidaemia is
related to the degree of glycaemic control and can take up
to 3 months to normalise. but at times the improvement of
the dyslipidaemia can be dramatic after treatment,
particularfy where gross lipaemia occurs. Obesity has a
greater influence on the lipid profile in NIDDM than in non-
diabetics. LDL-C is usually moderately increased.
Postprandial hyperlipidaemia is enhanced for various
reasons. This impairment of lipid metabolism is evident in
the non-diabetic offspring of NloOM patients who may only
have mild glucose intolerance;.l2 it is of interest that this is
mostly evident in the female offspring. The lipid
abnormalities in NIODM are more pronounced in females. In
summary, raised TG levels are seen with low HDl and
Variable LDL-e values.
Together with the quantitative changes in lipids, there are
also qualitative changes, with the production of small dense
LOL particles that are relativety TG-enriched and cholesterol-
depleted. and particularly atherogenic. Other compositional
changes of lipoprotein particles occur as described for
lOOM and these also do not normalise entirely after





is now agreed that l.p(a) levels are not higher in those with
uncomplicated NIODM than in normal controls. ol3 However,
significant increases were found in patients with CAD or
macro-angiopathy and l.p(a) may be an independent risk
factor for diabetes.
Are lipids the explanation for
the increased atherosclerosis
in diabetics?
Although the loL-C is not greatly increased in diabetics, the
relationship between cholesterol and CVD is still present'"
and the rates of CVD are three times higher in those with
NloDM than in non-diabetics. It would therefore be
reasonable to assume that quantitative changes in
lipoproteins are not the only explanation for the increase in
CVO in diabetes. Qualitative rather than quantitative
changes in lipids may well play a major role in the
development of atherosclerosis in patients with diabetes. In
lOOM renal disease is the major determinant of
cardiovascular disease" and as proteinuria is associated
with dyslipidaemia.<5 it is reasonable to assume that
dyslipidaemia plays a role in the development of
atherosclerosis. However, the excess cardiovascular
mortality in diabetics is not entirely explained by the lipid
profile, and other factors are probably operative.
Management of dyslipidaemia
in diabetes
The measures to be InstItuted should aIm to Improve
glycaemic control as well as Improve the lipid profile. Many
gUidelines for the management of dysllpldaemla have been
published. among them the NCEP goals.-'6 Goals for the
treatment of dyslipldaemia usually differentiate between men
and women. Because the dysllpldaemia. as well as the
mortality and morbidity from cardiovascular disease In
diabetes. IS the same for men and women, the same goals
should apply for both.
All the general non-pharmacological principles of
management of dyslipidaemia apply in diabetics. No large-
scale prospective study has demonstrated that these
measures are effective in reducing the Incidence of
macrovascular disease but there is every reason to believe
that these measures are effective and have the same
benefits as in non-diabetics. Furthermore, non-
pharmacological measures are highly cost-effective.
Lifestyle modification. In smokers HOl-C is reduced, the
susceptibility to oxidation of loL is increased, insulin
resistance is increased and the incidence of hypertension IS
increased. There is every reason to believe that these
parameters will improve with the cessation of smoking.
These patients should be enrolled into an active programme
with the necessary support if there is to be any hope of
success with this measure, and admonition on its own is
usually ineffective. Increased physical exercise should be
encouraged as this will be beneficial to glycaemic control,
obesity and the lipid profile.
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Diet. There is no role for high-fat diets in diabetes, and a
low-fat diet comprising less than 30% of calorie intake as
proposed by the NCEP is recommended. A high
carbohydrate intake also improves insulin sensitivity. An
increase in mono-unsaturated fat as provided in olive oil,
peanut oil and canola oil is recommended as this has been
shown to have a LOL-C-Iowering effect. Although omega-3
fatty acids can lower TG levels and improve platelet
aggregation, they can raise LDL-C and are not
recommended as a routine. A high-fibre diet is
recommended as beneficial in diabetics as well as those
with dyslipidaemia. An increase in protein is not
recommended because of the possibility of worsening of
renal function.
Glycaemic control. Because of the link between
glycaemic control and dyslipidaemia, optimal control of the
diabetes is the aim. SUlfonylureas can improve glucose
tolerance but may be linked to reduced HDL as well as
increased TG and cholesterol, which may be due partially to
the weight gain associated with these drugs. Metformin may
have independent lipid-lowering (TC and TG) effects47,"ll and
these effects are most marked when the TG level is high.
Although there are theoretical objections to the use of insulin
in NIDDM because of the possible deleterious effects of
hyperinsulinism, these have not been substantiated, and
insulin therapy should not be withheld from NIDDM patients
for fear of accelerating atherosclerosis.4.9 Overnight
insulinisation when VLDL production is at its highest may
well be beneficial to the lipid profile, However, many of the
beneficial effects of insulin may be offset by the weight gain
seen with insulin therapy. A new group of anti-diabetic
drugs, the thiazolidinediones, improve insulin resistance and
troglitazone improves TC, TG and HDL values as well as
reducing blood pressure in treated diabetic patients.50
Lipid-lowering drugs. Drugs to lower lipids should only
be used when the above measures have failed. However,
these drugs should not be withheld because, as is often the
case, an abnormal lipid profile is found and attributed to
poor control. Although the degree of dyslipidaemia is related
to poor glycaemic control, an abnormal lipid profile is part
and parcel of the disease process in NIDDM and insulin
resistance. Bile acid resins are not recommended because
they can dramatically increase the TG levels in patients with
hypertriglyceridaemia. The gastro-intestinal side-effects are
particularly troublesome in the presence of autonomic
neuropathy and po,?r compliance makes these drugs
extremely cost-ineffective. Nicotinic acid would appear to be
an ideal drug because it reduces TG and TC, and increases
HDL; it does, however, aggravate insulin resistance and
glucose intolerance ana increases uric acid levels, and is
therefore not recommended. Fibrates are the drugs of
choice as they reduce TG and raise HDL levels. Bezafibrate
improves insulin resistance but whether this applies to this
group of drugs as a whole is uncertain. The effect of fibrates
on fatal and non-fatal cardiovascular events remains to be
ascertained and there are some data to suggest that the
use of these drugs, notably clofibrate, increases non-
cardiovascular mortality. The HMG-CoA reductase inhibitors
or statins - simvastatin, pravastatin, f1uvastatin - are safe
in the treatment of dyslipidaemia of diabetes and mainly
reduce LDL-C with minor reductions in TG, although
atorvastatin has been shown to reduce TG rather
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dramatically. The statins furthermore do not adversely affect
insulin resistance. The statins also dramatically reduce fatal
and non-fatal cardiovascular events during treatment
without increasing non-cardiovascular or total mortality. A
sub-analysis of the 4S and WOSCOPS studies (secondary
and primary prevention, respectively) shows that these
benefits extend to diabetic patients and that these effects
may be more pronounced in women than men. These drugs
are recommended when fibrates have failed and may, in
fact, replace the fibrates as first choice once more data
become available.
Conclusion
Dyslipidaemia in diabetes should not be regarded merely as
the result of poor glycaemic control, but deserves rigorous
attention in its own right. Diligent efforts to optimise
glycaemic control and improve the abnormal lipid profile, as
well as attention to the other risk factors for atherosclerosis,
e.g. obesity and hypertension, are required jf an improved
long-term outcome in patients with diabetes is to be
realised.
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